Exelixis Inc

NASDAQ: EXEL
$23.53
-$0.18 (-0.8%)
Closing price April 25, 2024
Exelixis Inc is a pioneering oncology company dedicated to developing new treatments for challenging cancers. It is known for CABOMETYX tablets, aimed at advanced renal cell carcinoma patients, and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. Both drugs are based on cabozantinib, targeting multiple tyrosine kinases. Exelixis also works on COTELLIC for advanced melanoma and MINNEBRO for hypertension in Japan, among other innovative therapies. With a strong focus on research collaborations, Exelixis is at the forefront of cancer treatment advancements, headquartered in Alameda, California.
Piper Jaffray analyst have a list of top biotech stock picks that could bring big gains for investors. The look for high-conviction near-term binary events and lower conviction catalysts with...
Source: ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have already...
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set to take...
It is now getting close to the middle of May, and that means one thing for biotech investors.  The king of biotech and pharma events is about to take place.  The 2012 annual meeting of the American...
Source: Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Tuesday morning.Amgen Inc. (NASDAQ: AMGN) Reiterated...
The markets are beyond jittery.  From a massively overbought market discounting a recession entirely back to a market dominated by the woes of Europe.  The Europeans cannot get their bailouts...
Active traders and day traders have many stocks to choose from this Tuesday morning.  We are tracking news and moves in shares of Allied Irish Bank (NYSE: AIB), ARM Holdings PLC (NASDAQ:...
Active traders and day traders have many stocks to choose from this Thursday morning.  We are tracking news and moves in shares of Dry Ships, Inc. (NASDAQ: DRYS), Exelixis, Inc. (NASDAQ:...
There were many stocks in Biotech and BioHealth with plus-signs after their share prices today.  The BioHealth Business Daily is smoothing out the brief winners and losers to only weed out the...
The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis...
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down...
We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009.  At BioHealthInvestor.com we...
These are some of the other non-tech analyst upgrades and downgrades from Wall Street firms this Wednesday morning: Constellation Energy (CEG) Raised to Buy at Jefferies. Denny’s (DENN) Raised to...
Curis Inc. (NASDAQ: CRIS) shares down 18% after development partner Wyeth terminated their contract that focused on cancer treatment developments. Shares are down $0.29 to $1.14. The 52 week range is...
ABY raised to Neutral at UBS.AMD raised to neutral at Credit Suisse.AG raised to neutral at Credit Suisse.AEO raised to Outperform at Cowen.BLOG started as Outperform at Wachovia.DVA raised to Buy at...